Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Non-small Cell Lung Cancer Metastatic 2Neoplasms 2Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) 1Non-squamous Non-small Cell Lung Cancer 1Breast Cancer Metastatic 1Adenocarcinoma Gastric 1

Interventions

Gemcitabine 34pembrolizumab 27Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms × tusamitamab ravtansine × Clear all
NCT05429762 2025-04-06

TusaRav-QT

Sanofi

Phase 1 Terminated
56 enrolled
Tumor-Agnostic

Neoplasms

NCT02187848 2025-02-10

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

Sanofi

Phase 1 Terminated
254 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡